Acute Ischemic Stroke Interventional Study
A phase 1/2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 160 participants.
Also called NCT03803007
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 1/2
- Enrolled
- 160 participants
- Sponsor
- Acticor Biotech
- Registry
-
NCT03803007 -
2018-002855-13
-
- Other papers using this trial's data
- Safety and efficacy of platelet glycoprotein VI inhibition in acute ischaemic stroke (ACTIMIS): a randomised, double-blind, placebo-controlled, phase 1b/2a trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- France
- Registry status
- Completed
Technical summary
Registry record NCT03803007. Randomized; triple masking; primary purpose treatment. Start 2019-03-06 (actual); primary completion 2021-09-27 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Acute Ischemic Stroke Interventional Study
- Acronym
- ACTIMIS
- Condition
- Acute Ischemic Stroke
- Intervention (Drug)
- Intravenous ACT017 1000 mg
- Intervention (Other)
- Intravenous Placebo
- Lead sponsor
- Acticor Biotech
Record details
- Record id
cardio:ct-nct03803007- Content hash
8dfc191b7998dc6b86c1da1475294cd371d60eea9bcd6f9bc913b052c0492859